These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 20659000)
1. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Dick E; Rajamohan D; Ronksley J; Denning C Biochem Soc Trans; 2010 Aug; 38(4):1037-45. PubMed ID: 20659000 [TBL] [Abstract][Full Text] [Related]
2. Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy. Tan SH; Ye L J Cardiovasc Transl Res; 2018 Oct; 11(5):375-392. PubMed ID: 29557052 [TBL] [Abstract][Full Text] [Related]
3. Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes. Oh J; Kwon OB; Park SW; Kim JW; Lee H; Kim YK; Choi EJ; Jung H; Choi DK; Oh BJ; Min SH Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063213 [TBL] [Abstract][Full Text] [Related]
4. Probing flecainide block of I Geng L; Kong CW; Wong AOT; Shum AM; Chow MZY; Che H; Zhang C; Yau KL; Chan CW; Keung W; Li RA Toxicol Lett; 2018 Sep; 294():61-72. PubMed ID: 29758359 [TBL] [Abstract][Full Text] [Related]
5. Cardiomyocytes derived from human pluripotent stem cells for drug screening. Zeevi-Levin N; Itskovitz-Eldor J; Binah O Pharmacol Ther; 2012 May; 134(2):180-8. PubMed ID: 22269465 [TBL] [Abstract][Full Text] [Related]
6. Developmental cues for the maturation of metabolic, electrophysiological and calcium handling properties of human pluripotent stem cell-derived cardiomyocytes. Keung W; Boheler KR; Li RA Stem Cell Res Ther; 2014 Jan; 5(1):17. PubMed ID: 24467782 [TBL] [Abstract][Full Text] [Related]
7. Enhancing Maturation and Translatability of Human Pluripotent Stem Cell-Derived Cardiomyocytes through a Novel Medium Containing Acetyl-CoA Carboxylase 2 Inhibitor. Correia C; Christoffersson J; Tejedor S; El-Haou S; Matadamas-Guzman M; Nair S; Dönnes P; Musa G; Rohman M; Sundqvist M; Riddle RB; Nugraha B; Bellido IS; Johansson M; Wang QD; Hidalgo A; Jennbacken K; Synnergren J; Später D Cells; 2024 Aug; 13(16):. PubMed ID: 39195229 [TBL] [Abstract][Full Text] [Related]
8. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. Denning C; Borgdorff V; Crutchley J; Firth KS; George V; Kalra S; Kondrashov A; Hoang MD; Mosqueira D; Patel A; Prodanov L; Rajamohan D; Skarnes WC; Smith JG; Young LE Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1728-48. PubMed ID: 26524115 [TBL] [Abstract][Full Text] [Related]
9. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery. Steel D; Hyllner J; Sartipy P Curr Opin Drug Discov Devel; 2009 Jan; 12(1):133-40. PubMed ID: 19152222 [TBL] [Abstract][Full Text] [Related]
10. In vitro uses of human pluripotent stem cell-derived cardiomyocytes. Matsa E; Denning C J Cardiovasc Transl Res; 2012 Oct; 5(5):581-92. PubMed ID: 22639342 [TBL] [Abstract][Full Text] [Related]
12. Functional improvement and maturation of human cardiomyocytes derived from human pluripotent stem cells by barbaloin preconditioning. Yang H; Zhong W; Hamidi MR; Zhou G; Liu C Acta Biochim Biophys Sin (Shanghai); 2019 Sep; 51(10):1041-1048. PubMed ID: 31518384 [TBL] [Abstract][Full Text] [Related]
13. Use of Human Pluripotent Stem Cell Derived-Cardiomyocytes to Study Drug-Induced Cardiotoxicity. Maillet A; Tan KP; Brunham LR Curr Protoc Toxicol; 2017 Aug; 73():22.5.1-22.5.22. PubMed ID: 28777443 [TBL] [Abstract][Full Text] [Related]
14. Arrhythmogenicity Test Based on a Human-Induced Pluripotent Stem Cell (iPSC)-Derived Cardiomyocyte Layer. Slotvitsky M; Tsvelaya V; Frolova S; Dementyeva E; Agladze K Toxicol Sci; 2019 Mar; 168(1):70-77. PubMed ID: 30388253 [TBL] [Abstract][Full Text] [Related]
15. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Yang X; Pabon L; Murry CE Circ Res; 2014 Jan; 114(3):511-23. PubMed ID: 24481842 [TBL] [Abstract][Full Text] [Related]
16. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Rana P; Anson B; Engle S; Will Y Toxicol Sci; 2012 Nov; 130(1):117-31. PubMed ID: 22843568 [TBL] [Abstract][Full Text] [Related]
17. Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing. Shaheen N; Shiti A; Gepstein L Clin Pharmacol Ther; 2017 Aug; 102(2):203-208. PubMed ID: 28718902 [TBL] [Abstract][Full Text] [Related]
18. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760 [TBL] [Abstract][Full Text] [Related]
19. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells. Fonoudi H; Ansari H; Abbasalizadeh S; Larijani MR; Kiani S; Hashemizadeh S; Zarchi AS; Bosman A; Blue GM; Pahlavan S; Perry M; Orr Y; Mayorchak Y; Vandenberg J; Talkhabi M; Winlaw DS; Harvey RP; Aghdami N; Baharvand H Stem Cells Transl Med; 2015 Dec; 4(12):1482-94. PubMed ID: 26511653 [TBL] [Abstract][Full Text] [Related]
20. Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53-Dependent Apoptosis. Qiu XX; Liu Y; Zhang YF; Guan YN; Jia QQ; Wang C; Liang H; Li YQ; Yang HT; Qin YW; Huang S; Zhao XX; Jing Q J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]